Which biopharma CEO wowed you most this year?

STAT’s Adam Feuerstein is canvassing for 2019’s greatest biopharma chief executive, and wants your input. After all, there’s no number crunching or data analysis here; he’s just going on gut — and the insights of his loyal readers. So! Adam’s got four finalists for best CEO. 

There’s Ted Love of Global Blood Therapeutics — who led the company into a fast-paced approval of its sickle cell drug, Oxbryta. Then we have John Maraganore of Alnylam Pharmaceuticals, who won a second RNAi drug approval this past June. Clay Siegall of Seattle Genetics helped the cancer company build out its pipeline and double its stock price this year. And Onno van de Stolpe of Galapagos NV managed to negotiate a $5.1 billion research partnership with Gilead Sciences to advance treatments for a spate of diseases that affect the immune system.  

Vote here!